Tumors with high PD-L1 expression are more likely to respond to therapies that block the interaction between PD-1 on T cells and PD-L1 on tumor cells, thereby reactivating the immune response against the tumor [179,180]. The gene discussed is PDCD1; the disease is neoplasm.